Especifique uma ação ou criptomoeda na barra de pesquisa para obter um resumo
Beijing Konruns Pharmaceutical Co Ltd
603590Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon acutus hemocoagulase under Suling trade name, a single-component hemocoagulase clinical hemostatic drug for surgical operations. It is also involved in the development of drug candidates, including CX1026 for the treatment of lung, liver, kidney, colon, and skin T lymphocyte cancer; CX1003, which is in phase 1 trial for the treatment of solid tumors/preferably rare tumors; ZY5301 that is in phase 3 clinical trials for the treatment of chronic pelvic pain in sequelae of pelvic inflammatory disease; KC-B173 for bleeding and prevention of bleeding during surgical or invasive procedures; and KC1036, which is in phase 2 clinical trial for the treatment of solid tumors. The company was founded in 2003 and is headquartered in Beijing, China. Address: No. 11, Xingsheng South Road, Beijing, China
Analytics
Preço Alvo de Wall Street
322.02 CNYRácio P/E
34.4658Rendimento de dividendos
–Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Figuras chave 603590
Análise de Dividendos 603590
Crescimento de dividendos em 5 anos
–Crescimento contínuo
–Taxa de pagamento em média de 5 anos
36 %Histórico de Dividendos 603590
Avaliação de ações 603590
Relatório 603590
Acompanhe as principais métricas de cada ação em um só lugar, sem complicações
Inscreva-se no premiumResultados | 2019 | Dinâmica |